The interleukin-l receptor antagonist (IL-1Ra) is a member of the IL-1
family that binds to IL-1 receptors but does not induce any intracell
ular response. Two structural variants of IL-1Ra have previously been
described: a 17-kDa form that is secreted from monocytes, macrophages,
neutrophils, and other cells (sIL-1Ra) and an 18-kDa form that remain
s in the cytoplasm of keratinocytes and other epithelial cells, monocy
tes, and fibroblasts (icIL-1Ra). An additional 16-kDa intracellular is
oform of IL-1Ra has recently been described in neutrophils, monocytes,
and hepatic cells. Both of the major isoforms of IL-1Ra are transcrib
ed from the same gene through the use of alternative first exons. The
two promoters regulating transcription of the secreted and intracellul
ar forms have been cloned, and some of the functional cis-acting DNA r
egions have been characterized. The production of IL-1Ra is stimulated
by many substances including adherent IgG, other cytokines, and bacte
rial or viral components. The tissue distribution of IL-1Ra in mice in
dicates that sIL-1Ra is found predominantly in peripheral blood cells,
lungs, spleen, and liver, while icIL-1Ra is found in large amounts in
skin. Studies in transgenic and knockout mice indicate that IL-1Ra is
important in host defense against endotoxin-induced injury. IL-1Ra is
produced by hepatic cells with the characteristics of an acute phase
protein. Endogenous IL-1Ra is produced in numerous experimental animal
models of disease as well as in human autoimmune and chronic inflamma
tory diseases. The use of neutralizing anti-IL-1Ra antibodies has demo
nstrated that endogenous IL-1Ra is an important natural antiinflammato
ry protein in arthritis, colitis, and granulomatous pulmonary disease.
Treatment of human diseases with recombinant human IL-1Ra showed an a
bsence of benefit in sepsis syndrome. However, patients with rheumatoi
d arthritis treated with IL-1Ra for six months exhibited improvements
in clinical parameters and in radiographic evidence of joint damage.